This stock comparison places two very different businesses side by side. CATX is Perspective Therapeutics, a Seattle-area radiopharmaceutical company using the alpha-emitting isotope 212Pb to deliver targeted radiation to cancer cells. STRR is Star Equity Holdings, a Connecticut-based diversified holding company spanning modular construction, staffing, energy services, and investments. Investors evaluating relative performance and market positioning will find this comparison useful precisely because the two names sit at opposite ends of the risk spectrum: one is a binary, catalyst-driven biotech, while the other is a value-oriented, below-book micro-cap. Understanding how each behaves in the current environment helps clarify which profile may suit a given trading or investing strategy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Perspective Therapeutics develops next-generation radiopharmaceuticals, with three clinical-stage oncology programs — VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (FAP-positive solid tumors). Recent market activity has been volatile. The shares have trended sharply lower over the trailing three-month and twelve-month periods, and technical sentiment readings have skewed negative. Analyst sentiment has also cooled in recent weeks, with at least one major firm downgrading the stock and cutting price targets, while others have maintained Buy or Hold ratings across a wide target range.
What has influenced sentiment is a mix of positive pipeline news and persistent cash burn. The company secured an FDA Fast Track designation for PSV359 and a clinical collaboration with Merck to evaluate the candidate alongside Keytruda, developments that expanded its addressable market narrative. It also reported interim data at major oncology conferences. However, revenue remains minimal and quarterly net losses are substantial, even as a sizeable cash balance — roughly $271 million as of the most recent quarter — provides runway into late 2027. This combination of catalysts and elevated cash consumption has kept the stock rangebound and prone to sharp swings.
Star Equity Holdings operates four divisions: Building Solutions (modular and offsite construction), Business Services (Hudson Talent Solutions staffing), Energy Services (downhole tools for oil and gas, geothermal, and mining), and Investments (real estate and public/private positions). The company was reshaped by a mid-2025 merger with Hudson Global, which added meaningful staffing revenue and scale. Recent market activity has been comparatively steadier than CATX, with shares trading within a well-defined range over the past year. From what I see, the steadier price action stands out when compared to more volatile names in the sector.
Recent quarters have delivered double-digit revenue growth, with third-quarter revenue rising roughly 12% year over year, but the company has still posted net losses and missed some consensus estimates. Sentiment has been supported by factors including insider buying by the chief executive, a share repurchase program, declared dividends on its preferred stock, and a plan to monetize real estate through sale-leaseback transactions that could raise more than $9 million. The stock trades at a discount to book value, a key element of the value thesis. Offsetting this are thin cash reserves, shrinking revenue in the core staffing segment, and a backlog that has yet to justify management's $20 million quarterly revenue target for the building division.
The core contrast is one of business model and risk profile. CATX is a pre-revenue biotechnology company whose value hinges on clinical trial outcomes and regulatory milestones; its growth drivers are binary and event-driven. STRR is an operating conglomerate generating tens of millions in quarterly revenue, with growth tied to construction demand, staffing market conditions, and disciplined capital allocation.
On momentum, CATX has displayed significantly weaker recent price action and downgrade pressure, whereas STRR has been more rangebound with insider accumulation and buybacks providing a floor. On stability, STRR offers a tangible balance sheet and below-book valuation but carries thin liquidity and micro-cap volatility. On catalysts, CATX holds more headline potential through clinical readouts and partnerships, but that upside is paired with steep cash burn and dilution risk. Sector exposure differs entirely: healthcare/oncology versus diversified industrials and staffing. I’m watching this closely as the stability edge could matter in uncertain markets.
Weighing trend consistency, relative stability, and balance-sheet positioning, Tickeron's AI would currently lean toward STRR over CATX. The reasoning is probabilistic rather than definitive: STRR has shown a steadier trading range, active insider buying, a repurchase program, and a valuation below book value, all of which suggest firmer downside support. CATX, by contrast, sits in a pronounced downtrend with heavy cash burn and recent analyst downgrades, even though its clinical catalysts could eventually shift that picture. In the current environment, the AI's framework favors the name with greater relative stability and tangible asset backing.
In my view, running names like these through Tickeron’s AI Trading Bots helps surface patterns that manual review might miss, especially when comparing stability across different sectors. The platform’s rules-based approach provides a useful complement to traditional research without replacing judgment on catalysts or balance sheets. It has become a regular part of how I cross-check ideas before digging deeper into filings or news flow.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
STRR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 19, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 41 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STRR as a result. In 98 of 121 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
STRR moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STRR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for STRR entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for STRR's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +13.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where STRR advanced for three days, in 166 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
STRR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.563) is normal, around the industry mean (4.795). P/E Ratio (-3.292) is within average values for comparable stocks, (1.381). Projected Growth (PEG Ratio) (0.194) is also within normal values, averaging (1.448). Dividend Yield (0.000) settles around the average of (1.499) among similar stocks. P/S Ratio (0.171) is also within normal values, averaging (0.884).
The Tickeron Seasonality Score of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. STRR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STRR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer diagnostic imaging solutions and gamma cameras
Industry OtherConsumerServices